Skip to content
Menu
Your enquiry0
Products/Retatrutide
THE BATCHTIDE RANGEProduct packaging
Label detailsMinimum listed format shown

Metabolic research

RESEARCH USE ONLY

Retatrutide

LY3437943, LY-3437943

Retatrutide is a single peptide agonist of GIP, GLP-1 and glucagon receptors, studied across insulin secretion, food intake and energy expenditure. Select your format and quantity for pricing, batch availability and lead time.

CAS
2381089-83-2
Purity
>99%
Form
Lyophilized powder

Select a pack

8 options
Specification
5 mg / vial
Sales unit
box
Packaging
10 vials / box
Selected SKURT5

Minimum listed format shown. Refer to the selected SKU specifications; final packaging is confirmed with your quotation.

Test method: HPLC. Catalogue specification. Confirm the supplied batch against its COA.

Price, batch and delivery terms confirmed with your quotation.

✓ Batch-linked records✓ Private-label support✓ Multiple formats✓ Research use only

ABOUT THE MATERIAL

Product overview

Identity, scientific context and the details that distinguish this entry.

Retatrutide is a single peptide agonist of GIP, GLP-1 and glucagon receptors, studied across insulin secretion, food intake and energy expenditure.[Sources]

Its development code is LY3437943. The glucagon-receptor component adds a metabolic dimension to the GIP/GLP-1 receptor pairing, making receptor balance and integrated whole-body endpoints central to its pharmacology.

Research variables

Both engage GIPR and GLP-1R. Retatrutide also activates GCGR, allowing study of glucagon-associated energy expenditure alongside incretin-related responses. Each receptor should be measured separately before integrating metabolic endpoints.

A CLOSER LOOK

Mechanisms & published research

Read each finding with its study model and material identity.

01

A third receptor changes the metabolic question

The LY3437943 discovery study measured activity at GCGR, GIPR and GLP-1R. In obese mice, food-intake and energy-expenditure measurements helped distinguish the contributions of incretin-related and glucagon-related signaling. Early clinical work provided a separate pharmacokinetic and tolerability assessment.

02

From receptor design to a phase 2 endpoint

A randomized phase 2 study assessed a defined retatrutide formulation in adults with obesity or overweight and an associated condition. The endpoints included body-weight change over 24 and 48 weeks, gastrointestinal events and heart rate. These clinical measurements complement the receptor studies.

PRODUCT DATA

Specifications & identifiers

Product specifications and batch results are confirmed with your quotation and COA.

Product
Retatrutide
CAS
2381089-83-2
Molecular formula
C₂₂₁H₃₄₂N₄₆O₆₈
Molecular weight
4731.34 Da
Form
Lyophilized powder

Looking for the current-batch COA?

Review available records or add your document request to the enquiry.

View batch records ↗

BATCH DOCUMENTATION

Request the records you need

Add requirements to your enquiry. The team will confirm availability and scope for the offered lot.

01

Batch COA

Match the offered lot number, identity, test methods and reported results.

02

HPLC / MS records

Ask for available chromatograms and mass-identity records, including the method and reporting scope.

03

SDS & storage information

Confirm handling, transport and storage information for the offered material and packaging.

A document request adds no purchase quantity. Have a batch reference? Open batch records ↗

BEFORE YOU ENQUIRE

Common questions

How does it differ from tirzepatide?

Both engage GIPR and GLP-1R. Retatrutide also activates GCGR, allowing study of glucagon-associated energy expenditure alongside incretin-related responses. Each receptor should be measured separately before integrating metabolic endpoints.

How should storage and handling be confirmed?

Use the specification and available safety or stability information for the offered lot, form and packaging. Request written conditions before ordering; literature alone does not establish a universal temperature, shelf life or reconstitution procedure.

How are catalogue specifications checked against a batch?

The displayed value is a catalogue specification. Assess the offered lot against its matching COA and method. Chromatographic purity, component content and biological activity are different measurements; confirm which results are available.

What information helps with a quotation?

Include the exact SKU, quantity in boxes, destination, desired timing and document requirements. State any label or packaging needs. Pricing, availability, lead time and document scope are confirmed in the quotation.

SOURCES

References & technical sources

Content updated

  1. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. ↗

    Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. 2022, DOI: 10.1016/j.cmet.2022.07.013

    Receptor pharmacology and obese mice

  2. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. ↗

    Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, Retatrutide Phase 2 Obesity Trial Investigators. 2023, DOI: 10.1056/nejmoa2301972

    Randomized phase 2 trial in adults with obesity

  3. Retatrutide, KEGG DRUG D12430 ↗

    KEGG

    Chemical identity reference

Publications describe their own study materials and methods. They are distinct from BatchTide specifications and lot-release records. Materials listed here are for laboratory research only, not for human or veterinary use.

EXPLORE THE CATALOGUE

Related research materials

Explore related entries. Similar research contexts do not establish interchangeability.

WhatsApp support

Start a conversationTalk to our available support team.